Drugs / Trifluridine/tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07071844 | Sep 2025 → Dec 2028 expected | colorectal cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07071844 ↗ |
| Route | Oral | “35 mg/m², orally” NCT07071844 ↗ |